Bionano Genomics (BNGO) Accounts Payables (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Accounts Payables data on file, last reported at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 22.86% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (down 22.86% YoY), and the FY2025 full-year result was $5.6 million, down 19.71% from the prior year.
• Accounts Payables slipped to $5.1 million in Q1 2026, from $5.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $15.8 million in Q1 2023 to a low of $5.1 million in Q1 2026.
• A 5-year average of $9.0 million and a median of $8.7 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 198.33% in 2022 and plunged 43.39% in 2024, its largest moves.
• Tracing BNGO's Accounts Payables over 5 years: stood at $12.5 million in 2022, then dropped by 17.15% to $10.4 million in 2023, then tumbled by 32.95% to $7.0 million in 2024, then decreased by 19.71% to $5.6 million in 2025, then retreated by 9.45% to $5.1 million in 2026.
• Business Quant data shows BNGO's Accounts Payables at $5.1 million in Q1 2026, $5.6 million in Q4 2025, and $6.0 million in Q3 2025.